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Abstract
BACKGROUND: The emergence of a new strain of coronavirus infection, the coronavirus infection disease 
2019 (COVID-19), has been a pandemic burden across the globe. Severe COVID-19, particularly in patients with 
acute respiratory distress syndrome (ARDS), is associated with increased risk of admission to intensive care unit 
(ICU), mechanical ventilation, and mortality. Bronchoscopy has been widely employed as an adjunctive therapy in 
mechanically ventilated patients. However, the use of bronchoscopy in patients with COVID-19 has been strictly 
limited due to aerosol transmission.
CASE REPORT: We reported 3 COVID-19 Cases presented to the hospital with ARDS. All of the patients were 
immediately intubated to improve oxygenation. During admission, the patients produced immense airway secretions 
that might have resulted in partial airway obstruction. A conventional tracheal suctioning did not help to promote 
clinical improvement. We decided to perform bronchoscopy with controlled suctioning by following a very tight protocol 
to prevent aerosol formation. A significant clinical and respiratory improvement was observed in all patients following 
bronchoscopy. Three of them were transferred to regular ward, however, one patient died during hospitalization.
CONCLUSION: Bronchoscopic procedures may provide significant therapeutic benefits in severe COVID-19 
patients. However, it should be kept in mind that this procedure should only be performed with a rigorous protocol to 
reduce the risk of aerosol generation and subsequent viral transmission.
Introduction
The emergence of a new strain of coronavirus 
has been a pandemic burden across the globe. Due 
to the similarity in the genomic sequence and clinical 
consequence with the previous strains of coronavirus, 
it has later been named as severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) that causes 
a disease called coronavirus infection disease 2019 
(COVID-19) [1], [2]. Firstly reported in Wuhan, Hubei 
Province, China, by the end of December 2019, the 
number of confirmed SARS-CoV-2 infection cases 
has been dramatically increasing [3]. As per July 1, 
2020, there have been more than 10.6 million cases 
and over 514,000 COVID-19-related deaths reported 
by the World Health Organization. A substantial 
number of new cases has been published in the 
United States recently, making it the only country 
that reaches a total of more than 1 million confirmed 
cases.
On the other hand, although it has been 
reported to be steadily increasing, the incidence rates in 
Indonesia are not as overwhelmingly high, as stated in 
the different parts of the world. This may be attributed to 
the low rates of screening in our population. However, the 
case fatality rate of SARS-CoV-2 infection in Indonesia 
is relatively higher, indicated by the mortality rates of 
7.2% [4]. Severe COVID-19, particularly in patients 
with acute respiratory distress syndrome (ARDS), 
is associated with an increased risk of admission to 
the intensive care unit (ICU), mechanical ventilation, 
and mortality [5], [6]. It has been well documented 
that patients suffering from ARDS most probably 
produce thick mucus secretion. This is associated 
with an increased risk of mucous plug formation and 
subsequent lung collapse [7]. Similar characteristics of 
airway secretion have also been reported in COVID-19 
infection [8]. Proper and timely secretion management 
plays essential roles in both the prevention and 
treatment of respiratory failure. Bronchoscopy has 
been widely employed for various purposes in severe 
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pulmonary infection, particularly among mechanically 
ventilated patients. This includes therapeutic suctioning 
as a part of effective secretion management, both as 
diagnostic and therapeutic measures [7], [9], [10]. 
However, the use of bronchoscopy in patients with 
COVID-19 has been strictly limited as it is associated 
with the aerosol generation and intensifies viral 
transmission. It can be performed only in certain 
situations, such as mucous plug removal as well as to 
ascertain the presence of any coinfection in patients 
who do not respond to the standard therapy, by following 
a very tight protocol as proposed by currently available 
consensus [3], [11], [12], [13], [14]. However, to the best 
of our knowledge, there is no presently available data 
regarding the use of the bronchoscopic intervention in 
COVID-19 patients with severe clinical presentation. 
Here, we describe the outcomes of bronchoscopic 
intervention performed in three cases of mechanically 
ventilated, COVID-19-confirmed patients.
Case I
A 47-year-old woman was admitted to our 
facility due to shortness of breath accompanied cough 
since 1 day before admission. The patient also reported 
a 1-week course of fever, nausea, and vomitus. She 
had neither a history of lung nor heart disease. The 
patient was diagnosed with severe pneumonia. On 
the 3rd day of hospitalization, the patient experienced 
clinical deterioration with more intense dyspnea. 
The initial clinical examination showed decreased 
oxygen saturation (SpO2) to 84%, and the patient was 
immediately given oxygen supplementation. Arterial 
blood gas (ABG) analysis showed pH 7.480, PaCO2 
34.6 mmHg, PaO2 159.5 mmHg, and SpO2 98%. Chest 
X-ray results were suggestive for bilateral pneumonia 
(Table 1). The patient was decided to undergo early 
intubation with subsequent mechanical ventilation. The 
following ventilator setting was used: Volume-controlled 
synchronized intermittent mandatory ventilation 
(VC-SIMV) mode, a fraction of inspired oxygen (FiO2) 
70%, positive end-expiratory pressure (PEEP) 12 
cmH2O, pressure support 12 cmH2O, tidal volume 
(VT) 300 ml, and respiratory rate (RR) 20 breaths/
min that resulted in oxygen saturation (SpO2) of 98% 
immediately. One day following intubation, the patient 
showed clinical improvement. Subsequent blood gas 
analysis results showed improved PaO2 that reached 
195.5 mmHg. On the next day, from the physical 
examination, it was found that there was an excessive 
mucus production that might have partially obstructed 
the patient’s airway. We performed tracheal suctioning 
as the primary measure to evacuate the obstructing 
mucus; however, no clinical improvement was observed. 
Subsequently, we decided to perform controlled suction 
through bronchoscopy. Pre-bronchoscopy ABG showed 
pH 7.492, PaO2 150 mmHg, PaCO2 34 mmHg, and 
SpO2 99%. Even when there was no vivid hypoxemia, 
we considered that early bronchoscopic suction would 
be a favorable measure to improve the patient’s clinical 
status. The ventilator parameters before bronchoscopy 
were set as pressure support ventilation (PSV), PEEP 
+5 cmH2O, RR 19 breaths/min, VT 400 ml, FiO2 40%, 
and PS 6 cmH2O. Bronchoscopy was performed on day 
24 of hospitalization in a negative-pressured room. We 
use fentanyl, atracurium, and midazolam as sedation 
before bronchoscopy. Bronchoscopy was performed 
with Olympus TF180, and we found a large amount of 
thick reddish black-colored secretions were evacuated 
from the lower airway. Ventilator settings were adjusted 
to SIMV, PEEP +6 cmH2O, RR 15 breaths/mnt, VT 
360 ml, FiO2 70%, and PS 5 cmH2O. Immediate post-
bronchoscopy ABG evaluations showed the following 
results: pH 7.5230, pO2 242.9 mmHg, pCO2 29 mmHg 
(Figure 1). On the following days, the patient showed 
significant clinical and respiratory improvement. 
Weaning of the respiratory support was started on 
day 3 and was discharged from the ICU on 28 days of 
hospitalization.
Figure 1: Bronchsocopy showed thick reddish black colored 
secretions
Case II
A 70-year-old man was admitted to our facility 
due to cough and fatigue. After a series of examination, 
the patient was confirmed to have suffered from 
COVID-19 pneumonia. On day 16 post-hospital 
admission, the patient experienced worsening shortness 
of breath. Immediate ABG evaluation showed pH 7.48, 
PCO2 31.5 mmHg, PO2 121.3 mmHg, and SpO2 84.3%. 
Accordingly, he was decided to undergo endotracheal 
intubation with subsequent mechanical ventilation 
support with the following ventilator settings: VC-SiMV, 
VT 400 ml, PEEP 10, PSV 10, RR 12 breaths/minute, 
and FiO2 80%. A significant hemodynamic improvement 
was observed following mechanical ventilation. Around 
6 days following intubation, it was noted that the patient 
produced enormous airway secretions, as evidenced 
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by pulmonary auscultation showing significant 
pulmonary rales. Further, ABG showed pH 7.57, 
PCO2 26.6 mmHg, and PO2 145.3 mmHg. Similarly, 
tracheal suction was performed initially as an effort to 
evacuate the obstructing mucus. However, the attempt 
was not successful. Therefore, a controlled suction 
was also performed through bronchoscopy. We were 
able to evacuate the thick obstructing secretion from 
the lower respiratory tract. The bronchoscopy showed 
the presence of thick secretion obstructing the distal 
trachea, which was removed (Figure 2). Subsequently, 
the ventilatory settings were adjusted to SIMV, PEEP 
+6 cmH2O, RR 12 breaths/mnt, VT 360 ml, FiO2 60%, 
and PS 6 cmH2O after the procedure. The patient 
demonstrated clinical improvement. Subsequent ABG 
evaluation showed pH 7.52, PCO2 35.1 mmHg, and 
PO2 171.7 mmHg. Ventilator weaning was successfully 
attempted on day 16, and the patient was discharged 
from the ICU on 26 days of hospitalization.
Figure 2: Bronchoscopy showed thick secretion obstrutcting the 
ditstal trachea
Case III
A 75-year-old man was confirmed to have 
suffered from COVID-19 pneumonia. The patient 
had a history of diabetes mellitus, hypertension, and 
cardiac disease. On day 3 post-hospital admission, the 
patient experienced worsening shortness of breath and 
decreasing of saturation. Immediate ABG evaluation 
showed pH 7.5, PCO2 22.6 mmHg, PO2 60.3 mmHg, 
and SpO2 86%. Accordingly, he was decided to undergo 
endotracheal intubation with subsequent mechanical 
ventilation support with the following ventilator settings: 
VC-SiMV, VT 600 ml, PEEP 10, PSV 10, RR 12 
breaths/min, and FiO2 60%. A significant hemodynamic 
improvement was observed following mechanical 
ventilation. Around 7 days following intubation, tracheal 
suction was performed initially as an effort to evacuate 
thick and green mucoid obstructing mucus. However, 
the attempt was not successful. Therefore, a controlled 
suction was also performed through bronchoscopy. The 
bronchoscopy showed thick yellow mucoid secretion, 
hyperemic in entire bronchus lumen, and prone to bleed 
(Figure 3). There are no adjusting ventilatory settings. 
The patient demonstrated clinical improvement. 
Subsequent ABG evaluation showed pH 7.466, PCO2 
34.8 mmHg, and PO2 173.2 mmHg. Ventilator weaning 
was successfully attempted on day three, and the 
patient was discharged from the ICU on 15 days of 
hospitalization. Unfortunately, the patient had a cardiac 
arrest and died in the hospital ward.
Figure 3: Bronchoscopy showed thick yellow mucoid secretion and 
hyperemic bronchus lumen
Discussion
COVID-19 is an extremely infectious disease 
caused by a newly identified SARS-CoV-2 virus. It has 
affected more than 3.5 million individuals in almost 
every country within the past 4 months [4]. SARS-CoV-2 
is an enveloped, non-segmented, positive-sense, and 
single-stranded RNA virus that is considered a member 
of beta-coronavirus [15], [16]. The clinical presentations 
of COVID-19 vary among individuals. Some people 
may not have any signs and symptoms of infection and 
become carriers. Some others may develop symptoms 
within 14 days following the initial exposure to the 
viral particles [17], [18]. The majority of patients (81%) 
demonstrated mild symptoms; only 14% and 5% of 
patients presented with a severe and critical disease, 
respectively [19]. The most common symptoms reported 
include fever (83–98%), cough (50–80%), fatigue 
(34–69%), and dyspnea (20–40%) [5], [20], [21], [22]. 
Patients with severe manifestations may present with 
signs and symptoms of pneumonia, ARDS, sepsis, and 
septic shock [23]. Patients who initially present with mild 
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symptoms could also experience clinical progression 
toward more severe illness. Rapid progression can also 
be encountered in an otherwise healthy patient without 
any significant medical history.
Goh et al. reported a case with a similar pattern 
of progression affecting a 64-year-old Singaporean 
man. The patient presented to the hospital with mild 
symptoms since around 1 week before admission and 
rapidly deteriorated with severe hypoxemic respiratory 
failure within only 48 h following admission [24]. Other 
evidence also suggested that the median time of 
ARDS development was 2 days from the admission 
day [6]. All of our cases presented with relatively mild 
disease complaining of having some respiratory and 
constitutional symptoms, including fever, cough, fatigue, 
and dyspnea. Following the previous evidence, the first 
patient demonstrated rapid progression, of which she 
demonstrated worsening of her clinical status within 
3 days of admission. The second case, on the other 
hand, demonstrated a relatively slower clinical course, 
where the patient experienced an intense worsening of 
his complaints after 2 weeks of hospitalization.
One of the biggest concerns in COVID-
19 is a further compromise in respiratory function. It 
has been noted that COVID-19 patients, particularly 
those who develop ARDS, produce thick mucus 
secretion. This puts the patients at a substantial risk 
of developing airway obstruction due to plug formation 
and subsequent lung collapse [7], [8]. Hence, airway 
management and optimal oxygenation serve as the 
constructing pillars in the management of severe 
COVID-19 infection. The concept of early intubation 
in COVID-19 patients has been a matter of debate. 
It is noteworthy that mechanical ventilation itself can 
exacerbate functional and structural alterations in 
the lung and is related to the morbidity and mortality 
in ARDS [25]. Therefore, timely, but not premature, 
endotracheal intubation is always preferred [26]. In 
our cases, all of the patients experienced clinical 
deterioration. Both of the patients experienced 
respiratory alkalosis, as indicated by their ABG results. 
Hence, endotracheal intubation was performed, 
followed by mechanical ventilation which resulted in 
clinical improvement. During observation in the ICU, 
both patients showed clinically significant production 
of airway secretions, as evidenced by abnormal lung 
sound on physical examination. Conventional tracheal 
suction has failed to evacuate the airway secretion, 
and hence, bronchoscopy was scheduled to vacate 
the secretion and prevent further airway compromise. 
Conventionally, bronchoscopy has been widely used as 
a standard procedure in the setting of severe respiratory 
problems for both diagnostic and therapeutic purposes 
in patients with a critical illness [10]. Unfortunately, 
the practice of performing bronchoscopy during 
the COVID-19 pandemic has been very restricted. 
Bronchoscopy is considered an aerosol-generating 
procedure, and hence, it possesses a substantial 
risk of viral transmission to the surrounding and puts 
both medical professionals and unconfirmed patients 
at risk of getting the infection. Therefore, it is always 
recommended to consider the risks and benefits of 
performing bronchoscopy, particularly among patients 
with confirmed COVID-19 disease. The decision 
should be individualized based on the patient’s clinical 
condition. Once decided to perform a bronchoscopic 
Table 1: Characteristics of the presented patients
Parameters Patient 1 Patient 2 Patient 3
Age (years) 47 70 74
Sex Female Male Male
Symptoms
Fever Yes No Yes
Cough Yes Yes Yes
Myalgia or fatigue Yes Yes Yes
Headache No No No
Hemoptysis No No No
Diarrhea No No No
Dyspnea Yes No Yes
Comorbidities
Diabetes No No Yes
Hypertension No No Yes
Cardiovascular disease No No Yes
Chronic obstructive pulmonary disease No No No
Malignancy No No No
Chronic liver disease No No No
Immunosuppresion No No No
Vital signs at admission
Blood pressure (mmHg) 136/80 124/73 167/81
Heart rate (bpm) 103 68 98
RR (×/min) 30 20 28
Temperature (°C) 38 36 36.8
Oxygen saturation (%) 84% 88% 98%
Laboratory parameters*
Hemoglobin (g/dL) 11.3 11.2 16.4
White blood cell count (×10) 5820 7490 14690
Neutrophil count (×10) 80 56 91
Lymphocyte count (×10) 14 37 6
Platelet count (×10) 231 227 296
PT (s) 13.1 11.8 10.9
APTT (s) 37.4 40 25.9
D-dimer (mg/dL) 380 3480 2130
Albumin (g/L) 3.9 3.2 2.9
ALT (U/L) 39 19 40
AST (U/L) 52 21 25
Sodium 145 130 137
Potassium 3.6 4.1 3.9
Creatinine (mg/dl) 0.79 1.01 2.27
Ureum (mg/dl) 19 42 70
Swab results Yes Yes Yes
CRP 7.84 14.14 24.47
Radiographic signs of pneumonia Yes Yes Yes
Treatment
Antiviral Yes Yes Yes
Antifungal No No No
Antibiotic Yes Yes Yes
Antiparasitic Yes Yes Yes
High-dose Vitamin C Yes Yes Yes
Ventilator-related parameters
Onset to mechanical ventilation (days) 3 16 2
Modea VC-SIMV VC-SiMV VC-SiMV
Peak pressure (cmH2O)a 12 10 10
PEEP (cmH2O)a 12 10 10
FiO2 (%) 70% 80% 50%
Bronchoscopy-related parameters
Day of bronchoscopy 24 28 10
Onset to bronchoscopy (days) 31 31 13
Positioning Prone Prone Prone
Bronchoscope diameter (mm) 2.1 2.1 2.1
ETT diameter (mm) 7.5 7.5 7.5
BAL No No No
Monitoring
MAP (mmHg)
Baseline 83 86 93
During bronchoscopy 93 86 93
Oxygen saturation (%)
Baseline 99 99 99
During bronchoscopy 99 99 98
Outcomes
Discharged from hospital Yes Yes No
Discharged from ICU Yes Yes Yes
Dead No No Yes
ALT: Alanine aminotransferase, APTT: Activated partial thromboplastin time, AST: Aspartate 
aminotransferase, BAL: Bronchoalveolar lavage, CRP: C-reactive protein; PCO2: Carbon dioxide, 
ETT: Endotracheal tube, FiO2: Fractional concentration of inspired oxygen, ICU: Intensive care unit, 
LDH: Lactate dehydrogenase, LOS: Length of stay, MAP: Mean arterial pressure, PCT: Procalcitonin, 
PEEP: Positive end-expiratory pressure, PT: Prothrombin time, VC-SIMV: Volume-controlled synchronized 
intermittent mandatory ventilation, RR: Respiratory rate.
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intervention, it has to be done only in a negative-
pressure room and by a highly experienced clinician to 
minimize the amount of time needed to complete the 
response. It is recommended to perform bronchoscopy 
with general anesthesia as well as with muscle relaxant 
administration while avoiding emergent intubation 
to reduce the risk of aerosol generation. Standard 
personal protective equipment and disinfection protocol 
are highly warranted [14]. Indications for performing 
bronchoscopy during COVID-19 pandemic have been 
categorized into emergent, semi-urgent, and elective 
indications. Patients with symptomatic central airway 
obstruction related to either neoplasm, foreign body 
aspiration, or mucous plug; massive hemoptysis, 
tracheal stenosis, and stent migration should be 
referred for further bronchoscopic evaluation. As for 
the evaluation of lung nodules, mediastinal lymph node 
enlargement, whole pulmonary lavage, suspected lung 
infection in patients with impaired immune function, 
assessment of obliterative bronchiolitis in transplant 
recipients, as well as evaluation of lobar atelectasis, 
bronchoscopy is advised to be performed in a semi-
urgent manner. Among patients in an otherwise stable 
condition, elective bronchoscopy can be performed 
for tracheobronchomalacia evaluation, bronchial 
thermoplastic, cryobiopsy, as well as bronchoscopic 
lung volume reduction surgery [11], [14].
The role of bronchoscopy in the management 
of patients with a severe phenotype of COVID-19 
infection is minimal. Bronchial or pulmonary toileting is 
not recommended as a routine therapeutic intervention 
in these subsets of patients. However, therapeutic 
aspiration is advisable in patients with airway obstruction 
due to mucous impaction that impairs gas exchange 
function. In our cases, the main reasons for performing 
bronchoscopy were the evidence of enormous airway 
secretions, as evidenced by clinical examination. We 
decided to perform bronchoscopy-directed bronchial 
toilet as an effort to help to evacuate the abundant 
mucoid secretion in the patients lower respiratory 
tract and to prevent the formation of mucus plug. We 
performed this bronchoscopic intervention under a very 
secure protocol as proposed by various consensus. 
Following the response, the patients showed favorable 
clinical and hemodynamic outcomes. Weaning of the 
mechanical ventilation could be performed earlier 
with desirable results. One of the primary concerns 
in performing bronchoscopy is which technique would 
result in a limitation of infection spread while maintaining 
the safety of the procedure. Some data suggested that 
prone positioning is associated with a reduction in 
mortality in mechanically ventilated patients with severe 
ARDS and that bronchoscopy performed in a prone 
position is safe without significantly aggravating the risk 
of clinical deterioration [9], [27]. In addition, fiberoptic 
bronchoscopy performed in a prone position helps to 
avoid undesirable premature interruption of mechanical 
ventilation and consequent loss of physiological gains, 
an increase in intrapulmonary shunt, a fall in the 
oxygen saturation as well as elevated pulmonary artery 
resistance [9].
At present, there is no standardized 
recommendation on a ventilator setting during 
bronchoscopy. Guarracino et al. (2012) successfully 
and safely performed bronchoscopy by increasing FiO2 
to 1, reducing PEEP level and respiratory frequency to 
avoid an increase in PEEP while increasing inspiratory 
pressure to maintain minute volume and prevent an 
increase in carbon dioxide [9]. Some data suggested 
that bronchoscopic tube internal diameter of 4 mm 
is optimal and safer in patients with ARDS [7]. In a 
case series of patients with severe ARDS who were 
mechanically ventilated, Kalchiem-Dekel et al. (2018) 
showed that no significant hemodynamic compromise 
was observed during bronchoscopic aspiration and 
BAL procedures using a maximum internal diameter of 
4 mm and without changing the mode of mechanical 
ventilation except for 100% FiO2. However, significant 
oxygen desaturation and rising in COs2 pressure were 
observed in one patient. At last, 4 out of 7 patients 
survived 30 days following discharge from ICU [28].
Conclusion
Bronchoscopic procedures may provide 
significant therapeutic benefits in severe COVID-19 
patients. However, it should be kept in mind that this 
procedure should only be performed with a rigorous 
protocol to reduce the risk of aerosol generation and 
subsequent viral transmission. More well-designed studies 
are needed to elucidate further the role of bronchoscopic 
intervention among severely ill COVID-19 patients as well 
as addressing the most optimal and the safest ventilator 
setting during the procedure.
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